RE:RE:RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumorsIf note, outside of Car-T, adding co-stimulatory domains that other companies are trying to develop to add to exisitng cancer therapies has not borne much fruit.
Consequently, the approach that ONCY is taking with the development of pelareorep in combination with checkpoint and small molecule inibitors, bispecifics, CAR-T and ADCs, appears to be the approach that Big Pharma is now looking to take.